Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints.
Inhibikase Therapeutics has secured up to $275 million in financing from healthcare-focused investors, led by Soleus Capital. The company is advancing IkT-001Pro, an optimized prodrug of imatinib, into late-stage clinical trials as a potential first oral disease-modifying treatment for pulmonary arterial hypertension. The FDA has designated IkT-001Pro as a New Molecular Entity, making it eligible for exclusivity designations.
Inhibikase Therapeutics has completed enrollment of 120 participants across 32 U.S. sites in its Phase 2 '201' trial evaluating risvodetinib for untreated Parkinson's disease, with results expected in Q4 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.